Empowering breakthroughs in mRNA therapeutics

The 4th Annual mRNA-Based Therapeutics Summit featured insights from over 65 mRNA technology experts, including key figures from leading companies, to discuss advancements in mRNA vaccines and therapeutics across various disease areas. We shared our latest unique technologies that provide ideal support for scientists making breakthroughs at every stage of the mRNA-based therapeutics pipeline, from discovery to delivery.

Featured technologies

mRNA synthesis learning center

Resources for Takara IVTpro mRNA Synthesis System.

PrimeCap T7 RNA Polymerase (low dsRNA)

PrimeCap T7 RNA Polymerase (low dsRNA) is a modified form of T7 RNA polymerase that combines highly efficient cap-analog-dependent RNA synthesis with extremely low dsRNA generation, making it the ideal choice for researchers engaged in mRNA therapeutic research and development.

Takara IVTpro mRNA Synthesis System

A complete solution for synthesizing high-quality single-stranded mRNA containing your gene of interest with a cap structure and poly(A) sequence.

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2023 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.